For broader context on peptide regulation, safety frameworks, and research applications, explore our Research Library.
On February 27, 2026, Health Secretary Robert F. Kennedy Jr. made a statement on Joe Rogan’s podcast that sent shockwaves through the peptide research community. Kennedy announced that approximately 14 of the 19 peptides the FDA had placed on its Category 2 restricted list in 2023 — effectively banning compounding pharmacies from producing them — would be moved back to Category 1 within “a couple of weeks.”
That was over a month ago. As of today, the formal FDA reclassification has not been officially published.
The compounds in question include some of the most widely researched peptides in the field: BPC-157, TB-500, Ipamorelin, CJC-1295, MOTS-c, Thymosin Alpha-1, GHK-Cu, Selank, Semax, Epitalon, and others. Their placement on the Category 2 list in September 2023 didn’t eliminate demand — it pushed researchers and consumers toward gray-market and overseas suppliers with no quality controls or pharmaceutical oversight.
Kennedy acknowledged this directly, stating that the restrictions “created the gray market.” Scott Brunner, CEO of the Alliance for Pharmacy Compounding, put it plainly: “The black market and the gray market are running amok. American consumers would be a lot better off if FDA would allow compounding of peptides that have a demonstrated track record of safety.”
When NPR asked HHS for a timeline update, a spokesperson offered no details — only that the FDA’s goal is to ensure Americans have access to products “produced under appropriate quality standards.”
The direction is clear. The regulatory machinery is just moving slower than a podcast announcement. For the research community, the practical implication is straightforward: reclassification to Category 1 would not mean FDA approval. It would mean licensed compounding pharmacies could legally prepare these compounds with a physician’s prescription — a meaningful step toward regulated, quality-controlled access after two years of legal gray area. Five peptides with stronger safety concerns are expected to remain on the restricted list regardless of the reclassification outcome.
The Wellness World Is Eager for RFK Jr.’s Promised Move on Peptides — NPR, March 31, 2026
FDA Peptide Reclassification 2026: What It Means for Patients — Amanecia Health, March 2026